Introduction {#s1}
============

Cancer is a major health problem in the most parts of the world. Approximately 12.7 million cancer cases and 7.6 million cancer deaths are estimated to occur each year worldwide [@pone.0089340-Jemal1]. The prevention and treatment for cancers caused increasing financial burdens around the world [@pone.0089340-Thun1]. As a complex disease, cancer is strongly influenced by environmental and genetic factors, of which gene polymorphism is a critical cause for the difference of individual genetic susceptibility to cancer [@pone.0089340-Zaridze1]. Identification of the key gene polymorphisms that are associated with cancer risk is essential for predicting individual at risk.

The nucleotide-binding oligomerization domain containing 2 (*NOD2*) gene, also known as *CARD15*, is mapped to chromosome 16q21. NOD2 is a member of evolutionarily conserved Nod-like receptors (NLRs) family which share a tripartite structure of a C-terminal sensor domain (leucine-rich repeats, LRRs), a central nucleotide-binding oligomerization domain (NOD) and an N-terminal effector domain (CARD) [@pone.0089340-Deng1]. NOD2 participates in sensing components of microbial cell wall and has been reported to regulate apoptosis and chronic inflammatory conditions [@pone.0089340-Girardin1]. The most commonly studied polymorphisms included three missense mutations (rs2066842 C/T, rs2066844 C/T, rs2066845 C/G) and a frameshift mutation (rs2066847 insC). These four polymorphisms were located at coding regions and might affect the expression and function of NOD2 by altering amino acid. Recently, increasing studies investigated the relations between these four polymorphisms and disease risk.

The rs2066842, rs2066844, rs2066845 and rs2066847 polymorphisms were initially found to be associated with increased risk of Crohn's disease (CD) in 2001 to 2003 [@pone.0089340-Hugot1]. Subsequently, the relation between these polymorphisms and ulcerative colitis (UC) risk was revealed [@pone.0089340-Gazouli1]. In 2004, Kurzawski et al. first linked *NOD2* polymorphism to risk of colorectal cancer [@pone.0089340-Kurzawski1]. After that, increasing studies focused on the association between *NOD2* polymorphisms and risks of various cancers including gastric cancer, colorectal cancer, endometrial cancer, breast cancer, ovarian cancer, laryngeal cancer and so on. However, the results from the individual studies were inconsistent.

So far, no comprehensive meta-analysis has investigated the overall cancer risk in relation to *NOD2* polymorphisms, except for a meta-analysis only concerning colorectal cancer in 2010. To explore whether *NOD2* polymorphisms were associated with risks of overall cancer and specific cancer subtypes, we performed a meta-analysis on the association between the four most frequently studied *NOD2* polymorphisms (rs2066842 C/T, rs2066844 C/T, rs2066845 C/G and rs2066847 insC) and cancer risk in the present study.

Materials and Methods {#s2}
=====================

Identification and Eligibility of Relevant Studies {#s2a}
--------------------------------------------------

Literatures of electronic databases including PubMed and Web of Science were systematically searched using the search terms of "*NOD2/CARD15*", "polymorphism/mutation/variant" and "cancer/malignancy/neoplasm". References cited in each identified literatures were further searched manually to find potential available studies. We contacted the author for specific raw data if the data presented in the article were not sufficient. When overlapping data exists, only the latest study with the largest sample was selected for this meta-analysis. The last search date was July 1, 2013.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Studies included in the present meta-analysis must meet the inclusion criteria as follows: observational studies concerning the association between *NOD2* gene polymorphisms (rs2066842 C/T, rs2066844 C/T, rs2066845 C/G and rs2066847 insC) and cancer risks; studies published in English; studies with sufficient raw data for estimating odds ratios (OR) and their 95% confidence interval (CI); the control group of the studies should be in accordance with the Hardy Weinberg Equilibrium (HWE). The main reasons for exclusion were reviews or meta-analysis; animal experiments; not relevant to specific polymorphisms; duplicate publications; no raw data after contacting the author; studies not in English.

Data Extraction {#s2c}
---------------

Two authors (Jingwei Liu and Caiyun He) extracted the data from the included studies independently. The following information was extracted from each study: first author, year of publication, ethnicity of the population, numbers of cases and controls, detection methods of *NOD2* polymorphism and the source of the control group. The conflicts were resolved after discussion and consensus was finally reached on all of the extracted data.

Statistical Analysis {#s2d}
--------------------

The statistical analysis was performed by Stata software (Version 11.0; StataCorp, College Station, TX). ORs and their 95% CI were used to assess the strength of association between *NOD2* gene polymorphisms and cancer risks. P value \<0.05 was considered as statistically significant. Heterogeneity was measured by using Q statistic (P\<0.10 indicates significant heterogeneity between studies) and I-squared (I^2^) value [@pone.0089340-Higgins1]. A fixed-effects model using Mantel-Haenszel method [@pone.0089340-Mantel1] was performed to calculate the pooled ORs when heterogeneity between studies was not significant. Otherwise, a random-effects model using DerSimonian and Laird method [@pone.0089340-DerSimonian1] was applied. Sensitivity analysis was performed to explore heterogeneity when significant heterogeneity was indicated. Subgroup analyses were performed to explore the effects of cancer type and source of controls. Additionally, publication bias were evaluated qualitatively by performing funnel plots and assessed quantitatively by Begg's test [@pone.0089340-Begg1] and Egger's test [@pone.0089340-Egger1], respectively. P value\<0.05 for Begg's and Egger's tests indicates significant publication bias.

Results {#s3}
=======

Characteristics of the Included Studies {#s3a}
---------------------------------------

This meta-analysis was organized according to the PRISMA statement ([Checklist S1](#pone.0089340.s007){ref-type="supplementary-material"}). Totally 93 literatures were indentified through electronic databases after duplicates removal. After reviewing the titles and abstracts of the potential available articles, 57 records were excluded mainly because of no relevance, in vitro or animal experiments, reviews or meta-analysis. The left 36 full-text articles were further assessed for eligibility. Finally, 30 full-text articles with eligibility were included in this meta-analysis [@pone.0089340-Kurzawski1], [@pone.0089340-Ashton1]--[@pone.0089340-Ennas1]. The flow chart of article selection was presented in [Figure S1](#pone.0089340.s001){ref-type="supplementary-material"}.

The main characteristics of the studies included in this meta-analysis were summarized in [Table 1](#pone-0089340-t001){ref-type="table"}. All the included studies were case-control designed published in English. The populations of the studies were all Caucasians. Four studies consisting of 368 cases and 567 controls investigated the association of *NOD2* rs2066842 C/T (P268S) polymorphism and cancer risk; 16 studies including 4507 cases and 4780 controls studied the association of *NOD2* rs2066844 C/T (R702W) polymorphism and cancer risk; 14 articles including 4185 cases and 4474 controls investigated the association of *NOD2* rs2066845 C/G (G908R) polymorphism and cancer risk; for *NOD2* rs2066847/rs5743293 (3020insC) polymorphism, 25 studies consisting of 23167 cases and 28601 controls were included. The types of cancers studied in relation to *NOD2* polymorphisms included gastric cancer and MALT lymphoma, colorectal cancer (CRC), melanoma, endometrial cancer, pancreatic cancer, breast cancer, non-Hodgkin lymphoma, laryngeal cancer, lymphocytic leukaemia and ovarian cancer. Data concerning different cancers were treated as separate studies in the subgroup analysis.

10.1371/journal.pone.0089340.t001

###### Characteristics of eligible studies in this meta-analysis.

![](pone.0089340.t001){#pone-0089340-t001-1}

  Author                            Year       Ethnicity            Cancer type        Controls source   Case   Control    Genotyping method
  -------------------------------- ------ ------------------- ----------------------- ----------------- ------ --------- ---------------------
  rs2066842 C/T (P268S)                                                                                                  
  Roberts, R. L.                    2006     New Zealander       Colorectal cancer           PB          133      201            ARMS
  Wex, T.                           2008        German            Gastric cancer             PB          167      153          PCR-RFLP
  Szeliga, J.                       2008        Polish             Rectal cancer             HB           51      100          PCR-RFLP
  Hnatyszyn, A.                     2010        Polish            Gastric cancer             HB           17      113       Pyrosequencing
  rs2066844 C/T (R702W)                                                                                                  
  Debniak, T.                       2005        Polish               Melanoma                HB          470      649     Allele-specific PCR
  Papaconstantinou, I.              2005         Greek           Colorectal cancer          N.A.         104      100     Allele-specific PCR
  Rosenstiel, P.                    2006        German         Gastric MALT lymphoma         HB           83      308           Taqman
  Roberts, R. L.                    2006     New Zealander       Colorectal cancer           PB          133      201            ARMS
  Lakatos, P. L.                    2007       Hungarian         Colorectal cancer          N.A.         194      200            dHPLC
  Vogel, U.                         2007        Danish           Colorectal cancer           PB          355      753           CE-SSCP
  Tuupanen, S.                      2007        Finnish          Colorectal cancer           PB          953      508            ARMS
  Szeliga, J.                       2008        Polish             Rectal cancer             HB           51      100          PCR-RFLP
  Suchy, J.                         2008        Polish           Colorectal cancer           HB          350      350          PCR-RFLP
  Ture-Ozdemir, F.                  2008         Greek         Gastric MALT lymphoma         HB           56      51           PCR-RFLP
  Wex, T.                           2008        German            Gastric cancer             PB          159      150          PCR-RFLP
  Mockelmann, N.                    2009        German           Colorectal cancer           PB          1044     724           SNPlex
  Angeletti, S.                     2009        Italian           Gastric cancer             PB          170      156          PCR-ARMS
  Freire, P.                        2010      Portuguese         Colorectal cancer           PB          112      152        Real-time PCR
  Rigoli, L.                        2010        Italian           Gastric cancer             PB           60      87           PCR-RFLP
  Ashton, K. A.                     2010      Austrilian        Endometrial cancer           PB          213      291        Real-time PCR
  rs2066845 C/G (G908R)                                                                                                  
  Papaconstantinou, I.              2005         Greek           Colorectal cancer          N.A.         104      100          PCR-RFLP
  Debniak, T.                       2005        Polish               Melanoma                HB          470      649     Allele-specific PCR
  Rosenstiel, P.                    2006        German         Gastric MALT lymphoma         HB           83      308           Taqman
  Roberts, R. L.                    2006     New Zealander       Colorectal cancer           PB          133      201            ARMS
  Tuupanen, S.                      2007        Finnish          Colorectal cancer           PB          960      508            ARMS
  Lakatos, P. L.                    2007       Hungarian         Colorectal cancer          N.A.         194      200            dHPLC
  Vogel, U.                         2007        Danish           Colorectal cancer           PB          355      753           CE-SSCP
  Ture-Ozdemir, F.                  2008         Greek         Gastric MALT lymphoma         HB           56      51           PCR-RFLP
  Szeliga, J.                       2008        Polish             Rectal cancer             HB           51      100          PCR-RFLP
  Suchy, J.                         2008        Polish           Colorectal cancer           HB          350      350          PCR-RFLP
  Mockelmann, N.                    2009        German           Colorectal cancer           PB          1044     724           SNPlex
  Freire, P.                        2010      Portuguese         Colorectal cancer           PB          112      152        Real-time PCR
  Rigoli, L.                        2010        Italian           Gastric cancer             PB           60      87           PCR-RFLP
  Ashton, K. A.                     2010      Austrilian        Endometrial cancer           PB          213      291        Real-time PCR
  rs2066847/rs5743293 (3020insC)                                                                                         
  Nej, K.                           2004        Polish           Pancreatic cancer           HB          127      300     Allele-specific PCR
  Kurzawski, G.                     2004        Polish           Colorectal cancer           HB          556      300     Allele-specific PCR
  Alhopuro, P.                      2004        Finnish          Colorectal cancer           PB          926      348     Allele-specific PCR
  Huzarski, T.                      2005        Polish             Breast cancer             HB          462     1910     Allele-specific PCR
  Debniak, T.                       2005        Polish               Melanoma                HB          470      649     Allele-specific PCR
  Lubinski, J.                      2005        Polish                 Mixed                 HB          2850    1910     Allele-specific PCR
  Papaconstantinou, I.              2005         Greek           Colorectal cancer          N.A.         104      100     Allele-specific PCR
  Rothman, N.                       2006       Caucasian       Non-Hodgkin lymphoma         PB/HB        3069    3497            Mixed
  Forrest, M. S.                    2006   British, American   Non-Hodgkin lymphoma          PB          899     1433           Taqman
  Roberts, R. L.                    2006     New Zealander       Colorectal cancer           PB          133      201            ARMS
  Jaworowska, E.                    2006        Polish           Laryngeal cancer            HB          347     4102     Allele-specific PCR
  Irmejs, A.                        2006        Latvian                Mixed                 PB          420      974     Allele-specific PCR
  Lener, M. R.                      2006        Polish                 Mixed                 HB          4496    2068     Allele-specific PCR
  Lakatos, P. L.                    2007       Hungarian         Colorectal cancer          N.A.         194      200            dHPLC
  Vogel, U.                         2007        Danish           Colorectal cancer           PB          355      753           CE-SSCP
  Ennas, M. G.                      2008        Italian        Lymphocytic leukaemia         PB           39      109           Taqman
  Magnowski, P.                     2008        Polish            Ovarian cancer             HB          257     1910     Allele-specific PCR
  Szeliga, J.                       2008        Polish             Rectal cancer             HB           51      100             ASA
  Suchy, J.                         2008        Polish           Colorectal cancer           HB          607      607          PCR-RFLP
  Wex, T.                           2008        German            Gastric cancer             PB           47      48           PCR-RFLP
  Ture-Ozdemir, F.                  2008         Greek         Gastric MALT lymphoma         HB           56      51           PCR-RFLP
  Angeletti, S.                     2009        Italian           Gastric cancer             PB          170      156        Multiplex PCR
  Rigoli, L.                        2010        Italian           Gastric cancer             PB           60      87           PCR-RFLP
  Skibola, C. F.                    2010         Mixed         Non-Hodgkin lymphoma         PB/HB        6360    6636            Mixed
  Freire, P.                        2010      Portuguese         Colorectal cancer           PB          112      152        Real-time PCR

Abbreviations: PB: population-based; HB: hospital-based.

Associations of *NOD2* Polymorphisms with Cancer Risks {#s3b}
------------------------------------------------------

For *NOD2* rs2066842 C/T (P268S) polymorphism, carriers of TT or CT genotype were not significantly associated with cancer risk compared with wild-type CC genotype (TT vs. CC: OR = 2.48, 95% CI = 0.85--7.25, P = 0.097; CT vs. CC: OR = 1.32, 95% CI = 0.54--3.25, P = 0.543, [Table 2](#pone-0089340-t002){ref-type="table"}). Similarly, no significant relation was found in recessive effect model of (TT+CT) genotype comparing with CC genotype (OR = 1.74, 95% CI = 0.80--3.77, P = 0.163, [Figure 1](#pone-0089340-g001){ref-type="fig"}) or in allele analysis of T allele comparing with C allele (OR = 1.54, 95% CI = 0.74--3.21, P = 0.247) ([Table 2](#pone-0089340-t002){ref-type="table"}). Results from the subgroup analysis of *NOD2* rs2066842 polymorphism were presented in [Table S1](#pone.0089340.s003){ref-type="supplementary-material"}.

![Forest plot for the association between *NOD2* rs2066842 polymorphism and cancer risk (TT+CT vs. CC).](pone.0089340.g001){#pone-0089340-g001}

10.1371/journal.pone.0089340.t002

###### Meta-analysis results of the association between *NOD2* polymorphisms and cancer risks.

![](pone.0089340.t002){#pone-0089340-t002-2}

                                    Data set number        OR(95% CI)           P value     Model   P~het~    I^2^(%)
  -------------------------------- ----------------- ----------------------- ------------- ------- --------- ---------
  rs2066842 C/T (P268S)                                                                                      
  TT vs. CC                                3            2.48(0.85--7.25)         0.097        R      0.041     68.8%
  CT vs. CC                                3            1.32(0.54--3.25)         0.543        R      0.002     83.9%
  (TT+CT) vs. CC                           4            1.74(0.80--3.77)         0.163        R     \<0.001    84.8%
  T allele vs. C allele                    3            1.54(0.74--3.21)         0.247        R     \<0.001    87.6%
  rs2066844 C/T (R702W)                                                                                      
  TT vs. CC                                7          **3.77(1.30--10.93)**    **0.015**      F      0.970     0.0%
  CT vs. CC                               13          **1.34(1.01--1.76)**     **0.040**      R      0.033     46.5%
  (TT+CT) vs. CC                          16          **1.32(1.01--1.72)**     **0.041**      R      0.012     49.9%
  T allele vs. C allele                   13          **1.43(1.09--1.88)**     **0.010**      R      0.024     48.8%
  rs2066845 C/G (G908R)                                                                                      
  CG vs. GG                               11          **1.39(1.03--1.87)**     **0.030**      F      0.186     27.1%
  (CC+CG) vs. GG                          14          **1.32(1.01--1.72)**     **0.040**      F      0.216     21.9%
  C allele vs. G allele                   11          **1.40(1.05--1.88)**     **0.024**      F      0.235     21.8%
  rs2066847/rs5743293 (3020insC)                                                                             
  +/+ vs. −/−                              4          **3.42(1.59--7.40)**     **0.002**      F      0.514     0.0%
  +/− vs. −/−                             14          **1.35(1.06--1.72)**     **0.016**      R      0.010     54.0%
  (+/+ and +/−) vs. −/−                   25          **1.23(1.10--1.38)**    **\<0.001**     R      0.092     28.6%
  \+ vs. −                                13          **1.40(1.11--1.76)**     **0.004**      R      0.014     52.4%

R: random effect model; F: fixed effect model.

For *NOD2* rs2066844 C/T (R702W) polymorphism, individuals with TT or CT genotype were associated with increased risk of cancer compared with CC carriers, respectively (TT vs. CC: OR = 3.77, 95% CI = 1.30--10.93, P = 0.015; CT vs. CC: OR = 1.34, 95% CI = 1.01--1.76, P = 0.040, [Table 2](#pone-0089340-t002){ref-type="table"}). (TT+CT) genotype was associated with increased risk of cancer compared with wild-type CC genotype (OR = 1.32, 95% CI = 1.01--1.72, P = 0.041, [Figure 2](#pone-0089340-g002){ref-type="fig"}). In the subgroup analysis of cancer type, (TT+CT) genotype was associated with significantly increased risk of CRC (OR = 1.26, 95% CI = 1.03--1.53, P = 0.027) but no significant association was observed for gastric tumors ([Table S2](#pone.0089340.s004){ref-type="supplementary-material"}). In addition, T allele of *NOD2* rs2066844 C/T polymorphism was associated with significantly increased risk of cancer compared with C allele ([Table 2](#pone-0089340-t002){ref-type="table"}).

![Forest plot for the association between *NOD2* rs2066844 polymorphism and cancer risk (TT+CT vs. CC).](pone.0089340.g002){#pone-0089340-g002}

For *NOD2* rs2066845 C/G (G908R) polymorphism, CG genotype carriers were observed to be significantly associated with increased risk of cancer compared with GG carriers (OR = 1.39, 95% CI = 1.03--1.87, P = 0.030, [Table 2](#pone-0089340-t002){ref-type="table"}). Individuals with (CC+CG) genotype were significantly associated with increased risk of cancer in the overall analysis (OR = 1.32, 95% CI = 1.01--1.72, P = 0.040, [Figure 3](#pone-0089340-g003){ref-type="fig"}) and in gastric tumor subgroup (OR = 2.70, 95% CI = 1.39--5.25, P = 0.003, [Table S3](#pone.0089340.s005){ref-type="supplementary-material"}), but no significant association was observed in CRC subgroup. Additionally, C allele was associated with increased cancer risk compared with G allele.

![Forest plot for the association between *NOD2* rs2066845 polymorphism and cancer risk (CC+CG vs. GG).](pone.0089340.g003){#pone-0089340-g003}

For *NOD2* rs2066847/rs5743293 (3020insC) polymorphism, carriers of insC/insC or insC/− genotype were associated with increased cancer risk compared with wild-type −/− carriers, respectively (insC/insC vs. −/−: OR = 3.42, 95% CI = 1.59--7.40, P = 0.002; insC/− vs. −/−: OR = 1.35, 95% CI = 1.06--1.72, P = 0.016). Individuals with (insC/insC+insC/−) genotype were significantly associated with increased risk of cancer compared with −/− carriers (OR = 1.23, 95% CI = 1.10--1.38, P\<0.001, [Figure 4](#pone-0089340-g004){ref-type="fig"}). In the subgroup analysis of cancer type, (insC/insC+insC/−) genotype was significantly associated with increased risk of colorectal cancer, gastric cancer and MALT lymphoma, breast cancer, lung cancer, laryngeal cancer but not with urogenital cancer, pancreatic cancer, melanoma or non-Hodgkin lymphoma ([Table S4](#pone.0089340.s006){ref-type="supplementary-material"}). In the subgroup analysis of control source, (insC/insC+insC/−) genotype was significantly associated with increased cancer risk in hospital-based subgroup (OR = 1.25, 95% CI = 1.12--1.40, P\<0.001) but no significant association was observed in population-based subgroup ([Table S4](#pone.0089340.s006){ref-type="supplementary-material"}).

![Forest plot for the association between *NOD2* rs2066847 polymorphism and cancer risk ((+/+ and +/−) vs. −/−).](pone.0089340.g004){#pone-0089340-g004}

Heterogeneity Test, Sensitivity Analysis, and Publication Bias {#s3c}
--------------------------------------------------------------

For most comparisons for *NOD2* gene rs2066844 C/T, rs2066845 C/G and rs2066847 insC polymorphisms, no obvious heterogeneity was observed (I^2^\<50%). The exclusion of each single study did not significantly change the overall outcome, suggesting that the results of the meta-analysis were robust. However, in most comparisons of rs2066842 C/T polymorphism, significant heterogeneity was observed, which could not be fully explained by study design or subgroup analysis. The heterogeneity might result from the limited number of studies included. Besides, meta-regression was not performed to explore the source of the heterogeneity due to the limited study number.

The Begg's test and Egger's test were performed to quantitatively evaluate the publication bias of the studies. The detailed results for publication bias test were summarized in [Table 3](#pone-0089340-t003){ref-type="table"}. No significant publication bias was observed in this meta-analysis except two comparisons in *NOD2* rs2066847 insC polymorphism. In addition, funnel plots that qualitatively evaluated the publication bias of association between *NOD2* rs2066847 insC polymorphism and cancer risk was presented in [Figure S2](#pone.0089340.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0089340.t003

###### Publication bias.
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                                      Compared genotype     Begg\'s test   Egger\'s test         
  -------------------------------- ----------------------- -------------- --------------- ------ -----------
  rs2066842 C/T (P268S)                   TT vs. CC             0.52           0.602       1.35     0.405
                                          CT vs. CC             0.52           0.602       0.87     0.546
                                       (TT+CT) vs. CC           1.36           0.174       1.70     0.231
                                    T allele vs. C allele       0.52           0.602       1.04     0.488
  rs2066844 C/T (R702W)                   TT vs. CC            -0.75           0.453       0.00     0.997
                                          CT vs. CC             1.83           0.067       1.96     0.076
                                       (TT+CT) vs. CC           1.53           0.126       1.79     0.095
                                    T allele vs. C allele       1.95           0.051       2.00     0.071
  rs2066845 C/G (G908R)                   CG vs. GG             0.39           0.697       0.45     0.666
                                       (CC+CG) vs. GG           0.93           0.352       1.05     0.313
                                    C allele vs. G allele       0.08           0.938       0.26     0.800
  rs2066847/rs5743293 (3020insC)         +/+ vs. −/−            0.68           0.497       1.28     0.329
                                         +/− vs. −/−            1.46           0.143       2.53   **0.028**
                                    (+/+ and +/−) vs. −/−       1.03           0.304       1.88     0.073
                                          \+ vs. −              1.10           0.272       2.42   **0.034**

Discussion {#s4}
==========

Results from previous individual studies investigating the associations between *NOD2* polymorphisms and cancer risk were inconclusive. To our knowledge, this was the first comprehensive meta-analysis concerning the effect of *NOD2* rs2066842 C/T, rs2066844 C/T, rs2066845 C/G and rs2066847 insC polymorphisms on risks of overall cancer and specific cancer subtypes. By analyzing the data extracted from 30 full-text publications, we revealed that *NOD2* rs2066844 C/T, rs2066845 C/G and rs2066847 (3020insC) polymorphisms might be associated with increased cancer risk especially for gastrointestinal cancer but no significant association was observed between *NOD2* rs2066842 C/T polymorphism and cancer risk.

*NOD2* gene comprises 12 exons and encodes a protein consisting of 1040 amino acids. NOD2 recognized microbial pathogens located in the cytoplasm through the specific detection of conserved muramyl dipeptides and induced nuclear factor kappa B (NF-κB) activation via the RIP2/IKK pathway [@pone.0089340-Kersse1]. The NF-κB pathway acts to enhance the expression of proinflammatory molecules, thereby stimulating both adaptive and innate immune responses. In addition, NOD2 was implicated in programmed cell death and was known to be key regulator of chronic inflammatory conditions [@pone.0089340-Strober1]. Recent attention has been given to the role of *NOD2* polymorphisms in carcinogenesis. Of which, four polymorphisms (rs2066842 C/T, rs2066844 C/T, rs2066845 C/G and rs2066847 insC) were of great interest. However, results of the individual studies came up with inconsistent conclusions.

In this meta-analysis, *NOD2* rs2066842 polymorphism was not observed to be associated with cancer risk in all comparisons. Only four studies were analyzed in the pooled estimates and obvious heterogeneities were detected which could not be explained by subgroup analysis or solved by meta-regression. Therefore, further large-scale studies were required to validate the results. With respect to *NOD2* rs2066844, rs2066845 and rs2066847 polymorphisms, the dominant effect models of the three polymorphisms all indicated significantly increased cancer risk (OR for rs2066844 = 1.32; OR for rs2066845 = 1.32; OR for rs2066847 = 1.23) ([Table 2](#pone-0089340-t002){ref-type="table"}). The allele analysis found consistently increased cancer risk (OR for rs2066844 = 1.43; OR for rs2066845 = 1.40; OR for rs2066847 = 1.40) ([Table 2](#pone-0089340-t002){ref-type="table"}).

Different cancer has its distinct mechanisms of initiation and progression, in which polymorphisms of key genes play a critical role. The present meta-analysis unraveled that *NOD2* polymorphisms were observed of different associations with cancer in various cancer subgroups. The (TT+CT) genotype of rs2066844 conferred increased risk to CRC but not gastric cancer and MALT lymphoma; individuals with (CC+CG) genotype of rs2066845 were associated with higher risk of gastric cancer and MALT lymphoma rather than CRC; (insC/insC+insC/−) genotype carriers of rs2066847 were associated with increased risk of colorectal cancer, gastric cancer and MALT lymphoma, breast cancer, lung cancer, laryngeal cancer but not with urogenital cancer, pancreatic cancer, melanoma or non-Hodgkin lymphoma. Besides, the source of controls adopted would influence the associations of polymorphisms with cancer risks. In the present study, (insC/insC+insC/−) genotype carriers of rs2066847 were associated with increased cancer risk in subgroup of hospital-based but not in population-based. The above-mentioned results of subgroup analysis uncovered underlying information and deserved future concerns.

Inflammation may lead to carcinogenesis by stimulating continuous cell proliferation, inducing DNA damage, and arousing angiogenesis [@pone.0089340-Jackson1]. Mutations of *NOD2* gene have been linked to a number of chronic inflammatory diseases including Crohn's disease, atopic dermatitis and so on [@pone.0089340-Zhong1]. As NOD2 is implicated in microbial recognition and inflammatory reactions, the association of *NOD2* polymorphisms with cancer risk might due to the alteration of the ability of inducing immune response to bacteria which consequently results in the development of persistent bacterial infection or enhanced production of proinflammatory mediators. The three polymorphisms (rs2066844, rs2066845 and rs2066847) which were observed to be associated with increased risk of cancer in this meta-analysis were all located at the leucine-rich region (LRR) of NOD2 protein. The amino acid substitutions caused by these polymorphisms would alter protein function or splicing, thus influencing the role of NOD2 in the regulation of apoptosis and chronic inflammation and finally leading to cancer. As for functional studies, 3020insC variant, leading to a substitution in the 10th LRR followed by a premature stop codon, has been proved to be less active in the response to bacterial lipopolysaccharides, which might produce an increased inflammatory response [@pone.0089340-Ogura1]. Mice deficient in NOD1, NOD2, or RIPK2 exhibited increased susceptibility to bacteria, which arises from a decreased ability to recruit neutrophils and less production in proinflammatory and antimicrobial molecules [@pone.0089340-Rosenstiel1], [@pone.0089340-Frutuoso1]. Although the above-mentioned studies could, at least in part, explain the observed relation of *NOD2* polymorphisms with cancer risk, future investigations concerning the specific mechanism of *NOD2* polymorphisms in carcinogenesis are still required.

Several limitations should be acknowledged in this meta-analysis when interpreting the results. First, the sample size was not sufficiently large for the pooled analysis of *NOD2* rs2066842 C/T polymorphism and some subgroup analyses for *NOD2* rs2066844 C/T, rs2066845 C/G and rs2066847 insC polymorphisms. Second, all the included studies in the current meta-analysis were published in English, therefore publication bias might exist although the statistical test did not indicate it. Third, the ethnicities of all the available studies were Caucasian populations, which inevitably limited the generalizability of our conclusion on other populations. Fourth, obvious heterogeneities were observed in a few comparisons, which would limit the accuracy of certain associations. Finally, as other important data of environment factors such as smoking or drinking were not available for individual studies, we could not obtained results with adjustments by other co-variables.

Conclusion {#s5}
==========

To be concluded, this meta-analysis suggested that *NOD2* rs2066844 C/T, rs2066845 C/G and rs2066847 (3020insC) polymorphisms might be associated with increased cancer risk especially for gastrointestinal cancer. No significant association was observed between *NOD2* rs2066842 C/T polymorphism and cancer risk. Further large-scale and well-designed studies concerning different ethnicities are still needed to confirm the results of our meta-analysis.
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